These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

336 related articles for article (PubMed ID: 16094268)

  • 1. Initial fusion rates with recombinant human bone morphogenetic protein-2/compression resistant matrix and a hydroxyapatite and tricalcium phosphate/collagen carrier in posterolateral spinal fusion.
    Glassman SD; Dimar JR; Carreon LY; Campbell MJ; Puno RM; Johnson JR
    Spine (Phila Pa 1976); 2005 Aug; 30(15):1694-8. PubMed ID: 16094268
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical outcomes and fusion success at 2 years of single-level instrumented posterolateral fusions with recombinant human bone morphogenetic protein-2/compression resistant matrix versus iliac crest bone graft.
    Dimar JR; Glassman SD; Burkus KJ; Carreon LY
    Spine (Phila Pa 1976); 2006 Oct; 31(22):2534-9; discussion 2540. PubMed ID: 17047540
    [TBL] [Abstract][Full Text] [Related]  

  • 3. RhBMP-2 versus iliac crest bone graft for lumbar spine fusion: a randomized, controlled trial in patients over sixty years of age.
    Glassman SD; Carreon LY; Djurasovic M; Campbell MJ; Puno RM; Johnson JR; Dimar JR
    Spine (Phila Pa 1976); 2008 Dec; 33(26):2843-9. PubMed ID: 19092613
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Is lumbar facet fusion biomechanically equivalent to lumbar posterolateral onlay fusion?
    Toth JM; Foley KT; Wang M; Seim HB; Simon Turner A
    J Neurosurg Spine; 2017 May; 26(5):586-593. PubMed ID: 28156207
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Delivery of recombinant human bone morphogenetic protein-2 using a compression-resistant matrix in posterolateral spine fusion in the rabbit and in the non-human primate.
    Suh DY; Boden SD; Louis-Ugbo J; Mayr M; Murakami H; Kim HS; Minamide A; Hutton WC
    Spine (Phila Pa 1976); 2002 Feb; 27(4):353-60. PubMed ID: 11840099
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Posterolateral lumbar spine fusion with INFUSE bone graft.
    Glassman SD; Carreon L; Djurasovic M; Campbell MJ; Puno RM; Johnson JR; Dimar JR
    Spine J; 2007; 7(1):44-9. PubMed ID: 17197332
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Radiographic, biomechanical, and histological evaluation of rhBMP-2 in a 3-level intertransverse process spine fusion: an ovine study.
    Toth JM; Wang M; Lawson J; Badura JM; DuBose KB
    J Neurosurg Spine; 2016 Dec; 25(6):733-739. PubMed ID: 27367941
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Use of recombinant human bone morphogenetic protein-2 with local bone graft instead of iliac crest bone graft in posterolateral lumbar spine arthrodesis.
    Park DK; Kim SS; Thakur N; Boden SD
    Spine (Phila Pa 1976); 2013 May; 38(12):E738-47. PubMed ID: 23474598
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Recombinant human bone morphogenetic protein-2 on an absorbable collagen sponge with an osteoconductive bulking agent in posterolateral arthrodesis with instrumentation. A prospective randomized trial.
    Dawson E; Bae HW; Burkus JK; Stambough JL; Glassman SD
    J Bone Joint Surg Am; 2009 Jul; 91(7):1604-13. PubMed ID: 19571082
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lower dose of rhBMP-2 achieves spine fusion when combined with an osteoconductive bulking agent in non-human primates.
    Barnes B; Boden SD; Louis-Ugbo J; Tomak PR; Park JS; Park MS; Minamide A
    Spine (Phila Pa 1976); 2005 May; 30(10):1127-33. PubMed ID: 15897825
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Posterior lumbar interbody fusion using recombinant human bone morphogenetic protein type 2 with cylindrical interbody cages.
    Haid RW; Branch CL; Alexander JT; Burkus JK
    Spine J; 2004; 4(5):527-38; discussion 538-9. PubMed ID: 15363423
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical and radiographic analysis of an optimized rhBMP-2 formulation as an autograft replacement in posterolateral lumbar spine arthrodesis.
    Dimar JR; Glassman SD; Burkus JK; Pryor PW; Hardacker JW; Carreon LY
    J Bone Joint Surg Am; 2009 Jun; 91(6):1377-86. PubMed ID: 19487515
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Perioperative complications of recombinant human bone morphogenetic protein-2 on an absorbable collagen sponge versus iliac crest bone graft for posterior cervical arthrodesis.
    Crawford CH; Carreon LY; McGinnis MD; Campbell MJ; Glassman SD
    Spine (Phila Pa 1976); 2009 Jun; 34(13):1390-4. PubMed ID: 19440166
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Posterolateral lumbar intertransverse process spine arthrodesis with recombinant human bone morphogenetic protein 2/hydroxyapatite-tricalcium phosphate after laminectomy in the nonhuman primate.
    Boden SD; Martin GJ; Morone MA; Ugbo JL; Moskovitz PA
    Spine (Phila Pa 1976); 1999 Jun; 24(12):1179-85. PubMed ID: 10382242
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Use of recombinant human bone morphogenetic protein-2 to achieve posterolateral lumbar spine fusion in humans: a prospective, randomized clinical pilot trial: 2002 Volvo Award in clinical studies.
    Boden SD; Kang J; Sandhu H; Heller JG
    Spine (Phila Pa 1976); 2002 Dec; 27(23):2662-73. PubMed ID: 12461392
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy of rhBMP-2 versus iliac crest bone graft for posterior C1-C2 fusion in patients older than 60 years.
    Yan L; Chang Z; He B; Liu T; Wang X; Guo H; Hao D
    Orthopedics; 2014 Jan; 37(1):e51-7. PubMed ID: 24683657
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Graft resorption with the use of bone morphogenetic protein: lessons from anterior lumbar interbody fusion using femoral ring allografts and recombinant human bone morphogenetic protein-2.
    Pradhan BB; Bae HW; Dawson EG; Patel VV; Delamarter RB
    Spine (Phila Pa 1976); 2006 May; 31(10):E277-84. PubMed ID: 16648733
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The use of recombinant human bone morphogenetic protein 2 (rhBMP-2) to promote spinal fusion in a nonhuman primate anterior interbody fusion model.
    Hecht BP; Fischgrund JS; Herkowitz HN; Penman L; Toth JM; Shirkhoda A
    Spine (Phila Pa 1976); 1999 Apr; 24(7):629-36. PubMed ID: 10209790
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Simple carrier matrix modifications can enhance delivery of recombinant human bone morphogenetic protein-2 for posterolateral spine fusion.
    Akamaru T; Suh D; Boden SD; Kim HS; Minamide A; Louis-Ugbo J
    Spine (Phila Pa 1976); 2003 Mar; 28(5):429-34. PubMed ID: 12616152
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Use of recombinant human bone morphogenetic protein-2 as an adjunct in posterolateral lumbar spine fusion: a prospective CT-scan analysis at one and two years.
    Singh K; Smucker JD; Gill S; Boden SD
    J Spinal Disord Tech; 2006 Aug; 19(6):416-23. PubMed ID: 16891977
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.